Cesium toxicity: Difference between revisions

(Moved intro into Background as bullets; removed excessive bold from bullet lead-ins; added Prolonged QT DDX template)
(Strip excess bold text)
 
(One intermediate revision by the same user not shown)
Line 3: Line 3:
*Cesium (Cs) is an alkali metal in the periodic table below potassium and rubidium
*Cesium (Cs) is an alkali metal in the periodic table below potassium and rubidium
* Cesium chloride (CsCl) is the form most commonly encountered in human toxicity
* Cesium chloride (CsCl) is the form most commonly encountered in human toxicity
*Sold online and in alternative health stores as a purported cancer treatment based on '''"high pH therapy"''' — the unproven claim that alkalinizing acidic cancer cells will destroy them<ref name="Dalal2004">Dalal AK, Harding JD, Verdino RJ. Acquired long QT syndrome and monomorphic ventricular tachycardia after alternative treatment with cesium chloride for brain cancer. ''Mayo Clin Proc''. 2004;79(8):1065-1069.</ref>
*Sold online and in alternative health stores as a purported cancer treatment based on "high pH therapy" — the unproven claim that alkalinizing acidic cancer cells will destroy them<ref name="Dalal2004">Dalal AK, Harding JD, Verdino RJ. Acquired long QT syndrome and monomorphic ventricular tachycardia after alternative treatment with cesium chloride for brain cancer. ''Mayo Clin Proc''. 2004;79(8):1065-1069.</ref>
* No controlled clinical trial has demonstrated any anticancer efficacy of CsCl<ref name="Sessions2013"/>
* No controlled clinical trial has demonstrated any anticancer efficacy of CsCl<ref name="Sessions2013"/>
*Proponents often recommend CsCl combined with selenium, high-dose vitamins A and C, zinc, and amygdalin (laetrile)<ref name="Sessions2013"/>
*Proponents often recommend CsCl combined with selenium, high-dose vitamins A and C, zinc, and amygdalin (laetrile)<ref name="Sessions2013"/>
Line 11: Line 11:
** Occupational: electronics manufacturing, energy production (rare significant exposure)
** Occupational: electronics manufacturing, energy production (rare significant exposure)
* Toxicity threshold: intakes of ≥6 g/day have produced severe cardiac toxicity; even lower doses (1-3 g/day) can cause QTc prolongation over weeks of use<ref name="Pinter2014">Pinter A, et al. Clinical effects of cesium intake. ''Pharmacol Res''. 2014;36(1):36-44. doi:10.1016/j.phrs.2009.06.003</ref>
* Toxicity threshold: intakes of ≥6 g/day have produced severe cardiac toxicity; even lower doses (1-3 g/day) can cause QTc prolongation over weeks of use<ref name="Pinter2014">Pinter A, et al. Clinical effects of cesium intake. ''Pharmacol Res''. 2014;36(1):36-44. doi:10.1016/j.phrs.2009.06.003</ref>
*Cesium has an extremely long biological half-life (~110 days for the slow compartment), meaning toxicity '''resolves slowly''' over days to weeks after cessation<ref name="ATSDR">Toxicological Profile for Cesium. Agency for Toxic Substances and Disease Registry (ATSDR). 2004.</ref>
*Cesium has an extremely long biological half-life (~110 days for the slow compartment), meaning toxicity resolves slowly over days to weeks after cessation<ref name="ATSDR">Toxicological Profile for Cesium. Agency for Toxic Substances and Disease Registry (ATSDR). 2004.</ref>


===Mechanism of toxicity===
===Mechanism of toxicity===
*Cesium '''blocks delayed rectifier potassium channels (Iₖᵣ)''' on atrial and ventricular myocytes<ref name="Sessions2013"/>
*Cesium blocks delayed rectifier potassium channels (Iₖᵣ) on atrial and ventricular myocytes<ref name="Sessions2013"/>
*This prolongs '''phase 3 repolarization''' of the cardiac action potential → prolonged QT interval
*This prolongs phase 3 repolarization of the cardiac action potential → prolonged QT interval
*Creates substrate for '''early afterdepolarizations (EADs)''' → triggered arrhythmias
*Creates substrate for early afterdepolarizations (EADs) → triggered arrhythmias
*Cesium competes with potassium for transport through potassium channels, displacing K⁺ intracellularly → causes '''hypokalemia''' and '''hypomagnesemia''', which further exacerbate QTc prolongation<ref name="Pinter2014"/>
*Cesium competes with potassium for transport through potassium channels, displacing K⁺ intracellularly → causes hypokalemia and hypomagnesemia, which further exacerbate QTc prolongation<ref name="Pinter2014"/>
*Hypokalemia and bradycardia synergistically increase the arrhythmogenic substrate
*Hypokalemia and bradycardia synergistically increase the arrhythmogenic substrate
*Net effect: '''acquired long QT syndrome''' with high risk of [[Torsades de pointes|torsades de pointes]] and [[Ventricular tachycardia|ventricular tachycardia]]
*Net effect: acquired long QT syndrome with high risk of [[Torsades de pointes|torsades de pointes]] and [[Ventricular tachycardia|ventricular tachycardia]]


==Clinical features==
==Clinical features==
Line 50: Line 50:
*QTc prolongation may develop over days to weeks of oral CsCl use
*QTc prolongation may develop over days to weeks of oral CsCl use
*Cardiac arrhythmias may occur suddenly without warning
*Cardiac arrhythmias may occur suddenly without warning
*After cessation, QTc prolongation resolves slowly ('''days to weeks''') due to cesium's long half-life<ref name="Dalal2004"/>
*After cessation, QTc prolongation resolves slowly (days to weeks) due to cesium's long half-life<ref name="Dalal2004"/>


==Differential diagnosis==
==Differential diagnosis==
Line 93: Line 93:
**Plasma cesium level (reference range <10 μg/L)
**Plasma cesium level (reference range <10 μg/L)
**Urine cesium level
**Urine cesium level
**Levels confirm diagnosis but do '''not''' reliably correlate with QTc duration or arrhythmia severity
**Levels confirm diagnosis but do not reliably correlate with QTc duration or arrhythmia severity
**Treatment should '''not''' be delayed pending levels
**Treatment should not be delayed pending levels


===Diagnosis===
===Diagnosis===
*Clinical: history of CsCl supplement use + QTc prolongation + hypokalemia ± arrhythmia
*Clinical: history of CsCl supplement use + QTc prolongation + hypokalemia ± arrhythmia
*High index of suspicion needed in any cancer patient presenting with syncope, palpitations, or new arrhythmia — ask about CAM use
*High index of suspicion needed in any cancer patient presenting with syncope, palpitations, or new arrhythmia — ask about CAM use
*Cesium toxicity should be included in the differential diagnosis of '''unexplained acquired long QT syndrome'''<ref name="Lyon2003"/>
*Cesium toxicity should be included in the differential diagnosis of unexplained acquired long QT syndrome<ref name="Lyon2003"/>


==Management==
==Management==
Line 109: Line 109:
===Electrolyte repletion===
===Electrolyte repletion===
* Aggressive IV potassium repletion — target high-normal serum K⁺ (4.5-5.0 mEq/L) to counteract cesium's potassium-displacing effect
* Aggressive IV potassium repletion — target high-normal serum K⁺ (4.5-5.0 mEq/L) to counteract cesium's potassium-displacing effect
**Cesium-associated hypokalemia may be refractory to standard repletion; '''amiloride''' (a potassium-sparing diuretic that blocks the distal tubular sodium channel through which cesium enters) has been used successfully as adjunctive therapy<ref name="Horn2015">Horn S, Naidus E, Alper SL, Danziger J. Cesium-associated hypokalemia successfully treated with amiloride. ''Clin Kidney J''. 2015;8(3):335-338. doi:10.1093/ckj/sfv017</ref>
**Cesium-associated hypokalemia may be refractory to standard repletion; amiloride (a potassium-sparing diuretic that blocks the distal tubular sodium channel through which cesium enters) has been used successfully as adjunctive therapy<ref name="Horn2015">Horn S, Naidus E, Alper SL, Danziger J. Cesium-associated hypokalemia successfully treated with amiloride. ''Clin Kidney J''. 2015;8(3):335-338. doi:10.1093/ckj/sfv017</ref>
* IV magnesium sulfate — replete aggressively; magnesium is also first-line treatment for torsades de pointes
* IV magnesium sulfate — replete aggressively; magnesium is also first-line treatment for torsades de pointes
*Monitor electrolytes frequently (at least q4-6h initially)
*Monitor electrolytes frequently (at least q4-6h initially)
Line 131: Line 131:
**Available through the Radiation Emergency Assistance Center/Training Site (REAC/TS) or Strategic National Stockpile
**Available through the Radiation Emergency Assistance Center/Training Site (REAC/TS) or Strategic National Stockpile
* Hemodialysis: cesium is dialyzable given its low molecular weight and distribution similar to potassium; may be considered in severe life-threatening toxicity, though clinical data are limited
* Hemodialysis: cesium is dialyzable given its low molecular weight and distribution similar to potassium; may be considered in severe life-threatening toxicity, though clinical data are limited
*Note: even with treatment, QTc prolongation may take '''days to weeks''' to resolve due to cesium's long tissue half-life
*Note: even with treatment, QTc prolongation may take days to weeks to resolve due to cesium's long tissue half-life


===Supportive care===
===Supportive care===
Line 147: Line 147:
* All intentional ingestions: psychiatric evaluation mandatory prior to discharge
* All intentional ingestions: psychiatric evaluation mandatory prior to discharge
*Contact [[Poison control]] (1-800-222-1222 in the US) for all cases
*Contact [[Poison control]] (1-800-222-1222 in the US) for all cases
==Medication Dosing==
{{MedicationDose
| drug = Magnesium sulfate
| dose = 2g IV bolus
| route = IV
| context = First-line for QTc prolongation
| indication = Cesium toxicity
| population = Adult
}}


==See Also==
==See Also==

Latest revision as of 09:24, 22 March 2026

Background

  • Cesium toxicity is an uncommon but potentially fatal poisoning caused by ingestion of cesium chloride (CsCl), most commonly as a complementary and alternative medicine (CAM) "cancer treatment." The primary danger is severe QTc prolongation with resultant ventricular tachycardia, torsades de pointes, and cardiac arrest.[1]
  • Cesium (Cs) is an alkali metal in the periodic table below potassium and rubidium
  • Cesium chloride (CsCl) is the form most commonly encountered in human toxicity
  • Sold online and in alternative health stores as a purported cancer treatment based on "high pH therapy" — the unproven claim that alkalinizing acidic cancer cells will destroy them[2]
  • No controlled clinical trial has demonstrated any anticancer efficacy of CsCl[1]
  • Proponents often recommend CsCl combined with selenium, high-dose vitamins A and C, zinc, and amygdalin (laetrile)[1]
  • Patients frequently do not disclose CsCl use to their oncologists or emergency physicians
  • Cesium is also encountered in:
    • Radioactive form (¹³⁷Cs, ¹³⁴Cs): nuclear fission products; radiation exposure from nuclear accidents (managed with Prussian blue)
    • Occupational: electronics manufacturing, energy production (rare significant exposure)
  • Toxicity threshold: intakes of ≥6 g/day have produced severe cardiac toxicity; even lower doses (1-3 g/day) can cause QTc prolongation over weeks of use[3]
  • Cesium has an extremely long biological half-life (~110 days for the slow compartment), meaning toxicity resolves slowly over days to weeks after cessation[4]

Mechanism of toxicity

  • Cesium blocks delayed rectifier potassium channels (Iₖᵣ) on atrial and ventricular myocytes[1]
  • This prolongs phase 3 repolarization of the cardiac action potential → prolonged QT interval
  • Creates substrate for early afterdepolarizations (EADs) → triggered arrhythmias
  • Cesium competes with potassium for transport through potassium channels, displacing K⁺ intracellularly → causes hypokalemia and hypomagnesemia, which further exacerbate QTc prolongation[3]
  • Hypokalemia and bradycardia synergistically increase the arrhythmogenic substrate
  • Net effect: acquired long QT syndrome with high risk of torsades de pointes and ventricular tachycardia

Clinical features

Mild toxicity (early or low-dose)

  • GI distress: nausea, vomiting, diarrhea, decreased appetite
  • Numbness or tingling of the lips
  • Fatigue, muscle weakness
  • Hypotension, lightheadedness

Moderate to severe toxicity

  • Syncope (often the presenting complaint that brings patients to the ED)[5]
  • Palpitations
  • Seizures[2]

Cardiac toxicity (the primary life-threatening feature)

  • "Acquired long QT syndrome": QTc prolongation (reported up to >700 msec)[1]
  • Polymorphic ventricular tachycardia / Torsades de pointes — the most dangerous manifestation
  • Monomorphic ventricular tachycardia
  • R-on-T phenomenon
  • Premature ventricular contractions (PVCs)
  • Atrial fibrillation
  • Cardiac arrest (VT/VF)[1]

Electrolyte abnormalities

  • Hypokalemia — often severe; results from cesium displacing potassium[3]
  • Hypomagnesemia
  • Both electrolyte disturbances worsen QTc prolongation and arrhythmia risk

Timeline

  • QTc prolongation may develop over days to weeks of oral CsCl use
  • Cardiac arrhythmias may occur suddenly without warning
  • After cessation, QTc prolongation resolves slowly (days to weeks) due to cesium's long half-life[2]

Differential diagnosis

Acquired Long QT syndrome (other causes)

  • Drug-induced QTc prolongation (antiarrhythmics, antipsychotics, fluoroquinolones, antiemetics, methadone)
  • Hypokalemia (other causes)
  • Hypomagnesemia (other causes)
  • Hypocalcemia
  • Hypothermia
  • Myocardial ischemia

Other causes of syncope with arrhythmia

Other supplement/CAM toxicities


Prolonged QT interval

Evaluation

Workup

  • Detailed history of supplement/CAM use — the single most important diagnostic step
    • Patients often do not volunteer CsCl use; ask specifically about alternative cancer treatments, supplements, "high pH therapy," "alkalinization therapy"
    • Ask about concurrent supplement use (selenium, laetrile, high-dose vitamins)
  • 12-lead ECG: QTc measurement is critical[1]
    • QTc >500 msec is high-risk for torsades de pointes
    • Reported QTc values in cesium toxicity: 546-735 msec
    • Look for PVCs, R-on-T phenomenon, VT
  • Continuous cardiac monitoring on telemetry
  • Electrolytes: potassium, magnesium, calcium (expect hypokalemia and hypomagnesemia)
  • BMP: renal function
  • Troponin: usually negative (no structural heart disease); helps exclude ACS
  • Echocardiography: typically normal ventricular function; excludes structural causes
  • Cesium levels:
    • Whole blood cesium level (reference range <10 μg/L); levels >10,000 μg/L have been associated with fatal outcomes[1]
    • Plasma cesium level (reference range <10 μg/L)
    • Urine cesium level
    • Levels confirm diagnosis but do not reliably correlate with QTc duration or arrhythmia severity
    • Treatment should not be delayed pending levels

Diagnosis

  • Clinical: history of CsCl supplement use + QTc prolongation + hypokalemia ± arrhythmia
  • High index of suspicion needed in any cancer patient presenting with syncope, palpitations, or new arrhythmia — ask about CAM use
  • Cesium toxicity should be included in the differential diagnosis of unexplained acquired long QT syndrome[5]

Management

Immediate

  • Stop cesium chloride immediately
  • Continuous cardiac monitoring — high risk of VT/torsades
  • IV access; resuscitation equipment at bedside

Electrolyte repletion

  • Aggressive IV potassium repletion — target high-normal serum K⁺ (4.5-5.0 mEq/L) to counteract cesium's potassium-displacing effect
    • Cesium-associated hypokalemia may be refractory to standard repletion; amiloride (a potassium-sparing diuretic that blocks the distal tubular sodium channel through which cesium enters) has been used successfully as adjunctive therapy[6]
  • IV magnesium sulfate — replete aggressively; magnesium is also first-line treatment for torsades de pointes
  • Monitor electrolytes frequently (at least q4-6h initially)

Arrhythmia management

  • Torsades de pointes:
    • IV magnesium sulfate 2 g IV bolus (first-line)
    • Overdrive pacing (transvenous or transcutaneous) — increases heart rate to shorten QT interval and suppress EADs[2]
    • Isoproterenol infusion — temporizing measure to increase heart rate if pacing unavailable
    • Electrical cardioversion/defibrillation for hemodynamically unstable VT/VF
  • Monomorphic VT:
    • IV lidocaine — reported effective in cesium-induced VT[2]
  • Avoid class IA (procainamide, quinidine), class IC, and class III (amiodarone, sotalol) antiarrhythmics — all prolong QTc and will worsen the arrhythmogenic substrate[1]
  • Avoid other QTc-prolonging medications (ondansetron, droperidol, haloperidol, fluoroquinolones, etc.)

Enhanced elimination

  • Prussian blue (ferric hexacyanoferrate): 1 g PO three times daily[1]
    • Binds cesium in the GI lumen via ion exchange, preventing reabsorption and enhancing fecal excretion
    • FDA-approved for treatment of radioactive cesium (¹³⁷Cs) contamination; has been used off-label for stable cesium (CsCl) toxicity
    • Reduces biological half-life of cesium to approximately one-third of normal[4]
    • Available through the Radiation Emergency Assistance Center/Training Site (REAC/TS) or Strategic National Stockpile
  • Hemodialysis: cesium is dialyzable given its low molecular weight and distribution similar to potassium; may be considered in severe life-threatening toxicity, though clinical data are limited
  • Note: even with treatment, QTc prolongation may take days to weeks to resolve due to cesium's long tissue half-life

Supportive care

  • Seizure management: benzodiazepines first-line
  • Hemodynamic support as needed

Disposition

  • All patients with QTc prolongation from cesium: admit to ICU or cardiac-monitored setting
  • Continuous telemetry until QTc consistently <500 msec and no arrhythmias for 24-48 hours
  • Serial ECGs and electrolytes q4-6h initially, then q12h as QTc improves
  • QTc may remain prolonged for days to weeks — do not discharge prematurely
  • Cessation of CsCl is mandatory — counsel patient and family clearly that CsCl has no proven anticancer benefit and is life-threatening
  • Consider ongoing Prussian blue therapy if available
  • Follow-up with cardiology and oncology
  • All intentional ingestions: psychiatric evaluation mandatory prior to discharge
  • Contact Poison control (1-800-222-1222 in the US) for all cases

Medication Dosing

Magnesium sulfate 2g IV bolus IV

See Also

External Links

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 Sessions D, et al. Fatal Cesium Chloride Toxicity After Alternative Cancer Treatment. J Altern Complement Med. 2013;19(12):973-975. doi:10.1089/acm.2012.0731
  2. ↑ 2.0 2.1 2.2 2.3 2.4 Dalal AK, Harding JD, Verdino RJ. Acquired long QT syndrome and monomorphic ventricular tachycardia after alternative treatment with cesium chloride for brain cancer. Mayo Clin Proc. 2004;79(8):1065-1069.
  3. ↑ 3.0 3.1 3.2 Pinter A, et al. Clinical effects of cesium intake. Pharmacol Res. 2014;36(1):36-44. doi:10.1016/j.phrs.2009.06.003
  4. ↑ 4.0 4.1 Toxicological Profile for Cesium. Agency for Toxic Substances and Disease Registry (ATSDR). 2004.
  5. ↑ 5.0 5.1 Lyon AW, Mayhew WJ. Cesium toxicity: a case of self-treatment by alternate therapy gone awry. Ther Drug Monit. 2003;25(1):114-116.
  6. ↑ Horn S, Naidus E, Alper SL, Danziger J. Cesium-associated hypokalemia successfully treated with amiloride. Clin Kidney J. 2015;8(3):335-338. doi:10.1093/ckj/sfv017
Retrieved from "https://www.wikem.org/w/index.php?title=Cesium_toxicity&oldid=389045"